Armata Pharmaceuticals, Inc. 8-K

Summary

Delayed FY2025 results and clinical-development update. Armata needs more time to complete financial reporting and expects to file its 10-K by 3/31/2026, the due date. The FDA granted QIDP designation to AP-SA02 for intravenous adjunct treatment of complicated S. aureus bacteremia; Armata plans a Phase 3 trial after FDA feedback confirmed its Phase 2a data are sufficient to proceed.

Key Figures

• AP-SA02 Phase 2a diSArm: the AP-SA02 plus best available antibiotic therapy group had a 100% response rate without relapse at one week post-therapy and at 28 days; the placebo plus antibiotics group had ≈25% lack of response or relapse at both timepoints.
• Phase 3: planned to start in H2 2026, testing AP-SA02 against the current standard of care for complicated S. aureus bacteremia.
• QIDP designation makes AP-SA02 eligible for antibacterial-development incentives, including an additional five-year Hatch-Waxman market-exclusivity extension. Armata has also requested Fast Track designation.
• Los Angeles cGMP facility formally commissioned; full production runs completed. The facility is ≈56,000 square feet, including 10,000 square feet of clean rooms.

Investor Takeaways

• Watch for Phase 3 initiation in H2 2026 and the trial’s progress testing superiority over standard of care.
• Watch for the FDA’s decision on Armata’s Fast Track request and for the company’s 10-K filing by 3/31/2026.